Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 42Lymphoma 37Lymphoma, Mantle-Cell 35Lymphoma, Non-Hodgkin 32Multiple Myeloma 30Lymphoma, Follicular 30Hodgkin Disease 23Recurrence 19Lymphoma, Large B-Cell, Diffuse 19Lymphoma, B-Cell, Marginal Zone 18Waldenstrom Macroglobulinemia 12Leukemia 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, B-Cell 9Neoplasms, Plasma Cell 7Lymphoma, T-Cell 6Leukemia, Myeloid, Acute 6Burkitt Lymphoma 6Myelodysplastic Syndromes 5Leukemia, B-Cell 5Hematologic Neoplasms 5Sezary Syndrome 4Neoplasms 4Mycosis Fungoides 4Immune System Diseases 4Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Myeloproliferative Disorders 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell, Cutaneous 3

Interventions

Bendamustine Hydrochloride 3fludarabine 2Cyclophosphamide 2Brentuximab Vedotin 2pembrolizumab 1ibritumomab tiuxetan 1fludarabine phosphate 1Standard of Care 1Rituximab 1Radiotherapy 1Melphalan 1Etoposide 1Cytarabine 1Carmustine 1Bone Marrow Transplantation 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Lymphatic Diseases × Bendamustine Hydrochloride × Clear all
NCT03602157 2026-01-06

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

UNC Lineberger Comprehensive Cancer Center

Phase 1 Active not recruiting
43 enrolled
DermatologicLymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis

NCT03696784 2025-12-08

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

UNC Lineberger Comprehensive Cancer Center

Phase 1 Active not recruiting
19 enrolled
Lymphoid

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT02499627 2021-05-27

FIL-BBV

Fondazione Italiana Linfomi - ETS

Phase 2 Terminated
43 enrolled
Lymphoid

Lymphatic Diseases, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡